Technical Analysis for ERAS - Erasca, Inc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| Stochastic Reached Oversold | Weakness | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Inside Day | Range Contraction | -2.11% | |
| 20 DMA Resistance | Bearish | 0.54% | |
| MACD Bearish Centerline Cross | Bearish | 0.54% | |
| MACD Bearish Signal Line Cross | Bearish | 0.54% | |
| Earnings Movers | Other | 0.54% |
| Alert | Time |
|---|---|
| Down 3% | about 11 hours ago |
| Outside Day | about 13 hours ago |
| Fell Below Previous Day's Low | about 13 hours ago |
| Down 2 % | about 16 hours ago |
| 60 Minute Opening Range Breakdown | about 16 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/09/2024
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of NSCLC, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. The company was incorporated in 2018 and is headquartered in San Diego, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Acute Myeloid Leukemia Colorectal Cancer Enzymes Tyrosine Kinase Receptors Oncogenes NSCLC Non Small Cell Lung Carcinoma Metastatic Solid Tumors Bemcentinib Ras Gtpase Ptpn11
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Acute Myeloid Leukemia Colorectal Cancer Enzymes Tyrosine Kinase Receptors Oncogenes NSCLC Non Small Cell Lung Carcinoma Metastatic Solid Tumors Bemcentinib Ras Gtpase Ptpn11
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.375 |
| 52 Week Low | 1.51 |
| Average Volume | 614,580 |
| 200-Day Moving Average | 2.15 |
| 50-Day Moving Average | 2.07 |
| 20-Day Moving Average | 1.97 |
| 10-Day Moving Average | 2.05 |
| Average True Range | 0.14 |
| RSI (14) | 40.83 |
| ADX | 18.45 |
| +DI | 19.89 |
| -DI | 26.28 |
| Chandelier Exit (Long, 3 ATRs) | 1.85 |
| Chandelier Exit (Short, 3 ATRs) | 2.17 |
| Upper Bollinger Bands | 2.24 |
| Lower Bollinger Band | 1.70 |
| Percent B (%b) | 0.3 |
| BandWidth | 27.55 |
| MACD Line | -0.03 |
| MACD Signal Line | -0.01 |
| MACD Histogram | -0.0161 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.16 | ||||
| Resistance 3 (R3) | 2.18 | 2.09 | 2.11 | ||
| Resistance 2 (R2) | 2.09 | 2.02 | 2.09 | 2.09 | |
| Resistance 1 (R1) | 1.98 | 1.97 | 1.94 | 1.96 | 2.08 |
| Pivot Point | 1.89 | 1.89 | 1.87 | 1.89 | 1.89 |
| Support 1 (S1) | 1.78 | 1.82 | 1.74 | 1.76 | 1.64 |
| Support 2 (S2) | 1.69 | 1.77 | 1.69 | 1.63 | |
| Support 3 (S3) | 1.58 | 1.69 | 1.61 | ||
| Support 4 (S4) | 1.56 |
